Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity
- PMID: 34706248
- PMCID: PMC8636171
- DOI: 10.1016/j.ymthe.2021.10.007
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity
Figures
Erratum for
-
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.Mol Ther. 2021 May 5;29(5):1808-1820. doi: 10.1016/j.ymthe.2021.02.004. Epub 2021 Feb 9. Mol Ther. 2021. PMID: 33571680 Free PMC article.
Similar articles
-
Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.Oncotarget. 2017 Jul 11;8(28):45415-45431. doi: 10.18632/oncotarget.17557. Oncotarget. 2017. PMID: 28525366 Free PMC article.
-
Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.Cancer Immunol Immunother. 2021 Sep;70(9):2453-2465. doi: 10.1007/s00262-021-02856-0. Epub 2021 Feb 4. Cancer Immunol Immunother. 2021. PMID: 33543339
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.Mol Ther. 2020 May 6;28(5):1251-1262. doi: 10.1016/j.ymthe.2020.02.016. Epub 2020 Feb 24. Mol Ther. 2020. PMID: 32145203 Free PMC article.
-
Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.Cancer Lett. 2021 Apr 10;503:69-74. doi: 10.1016/j.canlet.2021.01.014. Epub 2021 Jan 19. Cancer Lett. 2021. PMID: 33476650 Review.
-
Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.Biomed Pharmacother. 2021 Jul;139:111573. doi: 10.1016/j.biopha.2021.111573. Epub 2021 Apr 22. Biomed Pharmacother. 2021. PMID: 33894623 Review.
Cited by
-
Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.Mol Ther. 2024 Mar 6;32(3):722-733. doi: 10.1016/j.ymthe.2024.01.035. Epub 2024 Feb 3. Mol Ther. 2024. PMID: 38311852
-
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.Curr Issues Mol Biol. 2023 Nov 12;45(11):9019-9038. doi: 10.3390/cimb45110566. Curr Issues Mol Biol. 2023. PMID: 37998743 Free PMC article. Review.
-
New insights in application of mesenchymal stem cells therapy in tumor microenvironment: pros and cons.Front Cell Dev Biol. 2023 Oct 2;11:1255697. doi: 10.3389/fcell.2023.1255697. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37849741 Free PMC article. Review.
-
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.Front Immunol. 2022 Jun 2;13:903562. doi: 10.3389/fimmu.2022.903562. eCollection 2022. Front Immunol. 2022. PMID: 35720364 Free PMC article. Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
